Silexion Therapeutics (SLXN) Competitors $0.85 +0.01 (+1.43%) As of 02:15 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock SLXN vs. MIRA, NNVC, FBLG, TPST, ALXO, QTTB, CVKD, TENX, CARA, and BCABShould you be buying Silexion Therapeutics stock or one of its competitors? The main competitors of Silexion Therapeutics include MIRA Pharmaceuticals (MIRA), NanoViricides (NNVC), FibroBiologics (FBLG), Tempest Therapeutics (TPST), ALX Oncology (ALXO), Q32 Bio (QTTB), Cadrenal Therapeutics (CVKD), Tenax Therapeutics (TENX), Cara Therapeutics (CARA), and BioAtla (BCAB). These companies are all part of the "pharmaceutical products" industry. Silexion Therapeutics vs. Its Competitors MIRA Pharmaceuticals NanoViricides FibroBiologics Tempest Therapeutics ALX Oncology Q32 Bio Cadrenal Therapeutics Tenax Therapeutics Cara Therapeutics BioAtla MIRA Pharmaceuticals (NASDAQ:MIRA) and Silexion Therapeutics (NASDAQ:SLXN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations. Do analysts rate MIRA or SLXN? MIRA Pharmaceuticals currently has a consensus target price of $14.00, indicating a potential upside of 702.29%. Silexion Therapeutics has a consensus target price of $5.00, indicating a potential upside of 485.48%. Given MIRA Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe MIRA Pharmaceuticals is more favorable than Silexion Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MIRA Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Silexion Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is MIRA or SLXN more profitable? Silexion Therapeutics' return on equity of 0.00% beat MIRA Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets MIRA PharmaceuticalsN/A -341.08% -272.93% Silexion Therapeutics N/A N/A -359.62% Which has higher valuation and earnings, MIRA or SLXN? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMIRA PharmaceuticalsN/AN/A-$7.85M-$0.51-3.42Silexion TherapeuticsN/AN/A-$16.44MN/AN/A Does the media favor MIRA or SLXN? In the previous week, MIRA Pharmaceuticals and MIRA Pharmaceuticals both had 1 articles in the media. Silexion Therapeutics' average media sentiment score of 1.89 beat MIRA Pharmaceuticals' score of 1.87 indicating that Silexion Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment MIRA Pharmaceuticals Very Positive Silexion Therapeutics Very Positive Which has more risk & volatility, MIRA or SLXN? MIRA Pharmaceuticals has a beta of 1.72, indicating that its share price is 72% more volatile than the S&P 500. Comparatively, Silexion Therapeutics has a beta of 0.05, indicating that its share price is 95% less volatile than the S&P 500. Do insiders and institutionals have more ownership in MIRA or SLXN? 35.2% of MIRA Pharmaceuticals shares are owned by institutional investors. Comparatively, 11.0% of Silexion Therapeutics shares are owned by institutional investors. 6.7% of MIRA Pharmaceuticals shares are owned by insiders. Comparatively, 6.0% of Silexion Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. SummaryMIRA Pharmaceuticals beats Silexion Therapeutics on 9 of the 11 factors compared between the two stocks. Get Silexion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SLXN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SLXN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLXN vs. The Competition Export to ExcelMetricSilexion TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.42M$3.04B$5.71B$9.51BDividend YieldN/A2.40%4.60%3.99%P/E RatioN/A21.1328.0720.02Price / SalesN/A338.95459.47103.02Price / CashN/A43.2336.5558.97Price / Book-0.348.278.615.88Net Income-$16.44M-$55.19M$3.24B$258.50M7 Day Performance3.15%5.50%3.83%2.03%1 Month Performance6.75%17.25%10.40%12.52%1 Year PerformanceN/A4.61%34.13%19.07% Silexion Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLXNSilexion TherapeuticsN/A$0.85+1.4%$5.00+485.5%N/A$7.42MN/A0.00N/APositive NewsMIRAMIRA Pharmaceuticals2.61 of 5 stars$1.54+20.3%$14.00+809.1%-26.3%$26.06MN/A-3.022High Trading VolumeNNVCNanoViricides0.3736 of 5 stars$1.60+14.7%N/A-31.3%$25.72MN/A-2.2220High Trading VolumeFBLGFibroBiologics3.8148 of 5 stars$0.64+1.7%$13.00+1,931.3%-86.2%$25.40MN/A-3.0510Positive NewsGap UpTPSTTempest Therapeutics2.3329 of 5 stars$6.90-0.7%$30.00+334.8%-71.7%$25.39MN/A-0.3820Positive NewsALXOALX Oncology3.8534 of 5 stars$0.47-2.8%$3.30+603.9%-91.3%$25.03MN/A-0.1940Positive NewsQTTBQ32 Bio2.5652 of 5 stars$2.03-23.7%$12.17+499.3%-93.6%$24.77M$1.16M-0.4139High Trading VolumeCVKDCadrenal Therapeutics3.1265 of 5 stars$12.50-3.3%$32.00+156.0%N/A$24.59MN/A-1.354Positive NewsTENXTenax Therapeutics1.8291 of 5 stars$5.90+1.7%$17.50+196.6%+77.6%$24.47MN/A-2.389Positive NewsCARACara Therapeutics0.2154 of 5 starsN/AN/AN/A$24.33M$7.14M-0.2580Gap DownHigh Trading VolumeBCABBioAtla2.1404 of 5 stars$0.40+4.0%$5.00+1,153.1%-78.0%$23.31M$11M-0.3360 Related Companies and Tools Related Companies MIRA Pharmaceuticals Alternatives NanoViricides Alternatives FibroBiologics Alternatives Tempest Therapeutics Alternatives ALX Oncology Alternatives Q32 Bio Alternatives Cadrenal Therapeutics Alternatives Tenax Therapeutics Alternatives Cara Therapeutics Alternatives BioAtla Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SLXN) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silexion Therapeutics Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share Silexion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
